Consensus ResMed, Inc.

Equities

RMD

US7611521078

Real-time Estimate Cboe BZX Other stock markets 11:45:07 2024-04-23 am EDT			5-day change	1st Jan Change
183.6 ^USD	+1.80%		-0.62%	+6.80%

Apr. 17	Wall St set for higher open on megacaps boost; earnings, Fed comments on tap	RE
Apr. 01	Needham Adjusts ResMed's Price Target to $224 From $180, Maintains Buy Rating	MT

Evolution of the average Target Price on ResMed, Inc.

Price target over the last 5 years

History of analyst recommendation changes

96.Qew4-nsEIiR_CL14jrGCsP5sL4BEziB9uSspjL9BCiA.M6Vdky1WR20KO-oR3sHN3J8dX7QAvBE1_X57wJILQkMewVmxTXNFSjBd3g~f2028d308dda21288dbb999b6ce18228

Analyst Recommendations on ResMed, Inc.

Needham Adjusts ResMed's Price Target to $224 From $180, Maintains Buy Rating	Apr. 01	MT
Morgan Stanley Adjusts Resmed’s Price Target to AU$31.80 From AU$28.60, Keeps at Overweight	Mar. 05	MT
Evans & Partners Upgrades ResMed to Positive From Neutral, Price Target is AU$31	Mar. 04	MT
Powell, the paper tiger	Feb. 05
ANALYST RECOMMENDATIONS : Abbvie, Microsoft, Tesla, Alphabet, Booking...	Feb. 05
Mizuho Adjusts Price Target on ResMed to $215 From $195, Keeps Buy Rating	Jan. 30	MT
Oppenheimer Raises ResMed Price Target to $205 From $185, Maintains Outperform Rating	Jan. 30	MT
UBS Adjusts ResMed Price Target to $180 From $175, Maintains Neutral Rating	Jan. 25	MT
Oppenheimer Raises ResMed Price Target to $185 From $175, Maintains Outperform Rating	Jan. 25	MT
RBC Lifts Price Target on ResMed to $182 From $181, Cites 'Solid' Fiscal Q2 Results, Keeps Sector Perform Rating	Jan. 25	MT
RBC Cuts Price Target on ResMed to $181 From $200, Keeps Sector Perform Rating	Jan. 22	MT
JPMorgan Adjusts Price Target on ResMed to $195 From $160, Maintains Overweight Rating	Jan. 09	MT
Nvidia comes to Wall Street's rescue	Jan. 09
ANALYST RECOMMENDATIONS : Blackrock, Blackstone, Exxon Mobil, Netflix, Charles Schwab...	Jan. 09
Joe Biden and Xi Jinping almost made up	Nov. 16
ANALYST RECOMMENDATIONS : Abbvie, Burberry, Chevron, Cisco, M&S...	Nov. 16
North American Morning Briefing : Rate Decisions, -2-	23-10-30	DJ
Morgan Stanley Upgrades Resmed to Overweight From Equalweight, Adjusts Price Target to AU$26 From AU$27.70	23-10-30	MT
Morgan Stanley Upgrades ResMed to Overweight From Equalweight, Adjusts Price Target to $169 From $180	23-10-27	MT
RBC Trims Price Target on ResMed to $200 From $202, Keeps Sector Perform Rating	23-10-27	MT
BofA Securities Adjusts ResMed Price Target to $220 From $230, Maintains Buy Rating	23-10-17	MT
Oppenheimer Cuts Price Target on ResMed to $175 From $275, Maintains Outperform Rating	23-10-16	MT
Earnings season starts with PepsiCo	23-10-10
Earnings season starts with PepsiCo	23-10-10
ANALYST RECOMMENDATIONS : Dollar General, Estee Lauder, ResMed, Tesla, Ulta Beauty...	23-10-10

More recommendations

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

180.4 USD

Average target price

206.1 USD

Spread / Average Target

+14.25%

High Price Target

258 USD

Spread / Highest target

+43.06%

Low Price Target

164 USD

Spread / Lowest Target

-9.07%

Consensus detail

Consensus revision (last 18 months)

Analysts covering ResMed, Inc.

Needham & Co.
Morgan Stanley
Evans & Partners
Mizuho Securities
Oppenheimer
UBS
RBC Capital Markets
JPMorgan Chase
BofA Securities
Wolfe Research
KeyBanc Capital Markets
JMP Securities
Jefferies & Co.
Citigroup
Goldman Sachs
Baird
Macquarie
J.P. Morgan Chase

Ratings for ResMed, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

B+

More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar